Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease

Research output: Contribution to journal › Review › Research › peer-review

Standard

Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. / Nielsen, Ole Haagen; Boye, Theresa Louise; Chakravarti, Deepavali; Gubatan, John.

In: Trends in Pharmacological Sciences, Vol. 43, No. 5, 2022, p. 424-436.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Nielsen, OH, Boye, TL, Chakravarti, D & Gubatan, J 2022, 'Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease', Trends in Pharmacological Sciences, vol. 43, no. 5, pp. 424-436. https://doi.org/10.1016/j.tips.2022.02.008

APA

Nielsen, O. H., Boye, T. L., Chakravarti, D., & Gubatan, J. (2022). Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends in Pharmacological Sciences, 43(5), 424-436. https://doi.org/10.1016/j.tips.2022.02.008

Vancouver

Nielsen OH, Boye TL, Chakravarti D, Gubatan J. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends in Pharmacological Sciences. 2022;43(5):424-436. https://doi.org/10.1016/j.tips.2022.02.008

Author

Nielsen, Ole Haagen ; Boye, Theresa Louise ; Chakravarti, Deepavali ; Gubatan, John. / Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. In: Trends in Pharmacological Sciences. 2022 ; Vol. 43, No. 5. pp. 424-436.

Bibtex

@article{d566789356ba4a03adc5af98895ebbf1,

title = "Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease",

abstract = "Recent significant advances have been made in the treatment of chronic inflammatory diseases with initiation of the era of biologics. However, an unmet medical need still exists for novel targeted therapies. Compared with biologics, Janus kinase inhibitors (JAKis) are a new drug class of orally administered small molecules that have been shown to efficiently modulate complex cytokine-driven inflammation in preclinical models and human studies. Unfortunately, serious adverse effects have been reported with the first introduced pan-JAKi, tofacitinib. Here, we review tyrosine kinase 2 (TYK2) signaling in the pathophysiology of inflammatory bowel disease (IBD), examine mechanisms of action of selective TYK2 inhibitors (TYK2is), and discuss the potential for these inhibitors in efforts to balance benefits and harms.",

keywords = "Crohn disease, Janus kinase, signal transducers and activators of transcription, small molecules, therapy, tyrosine kinase 2, ulcerative colitis",

author = "Nielsen, {Ole Haagen} and Boye, {Theresa Louise} and Deepavali Chakravarti and John Gubatan",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

doi = "10.1016/j.tips.2022.02.008",

language = "English",

volume = "43",

pages = "424--436",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd. * Trends Journals",

number = "5",

}

RIS

TY - JOUR

T1 - Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease

AU - Nielsen, Ole Haagen

AU - Boye, Theresa Louise

AU - Chakravarti, Deepavali

AU - Gubatan, John

PY - 2022

Y1 - 2022

N2 - Recent significant advances have been made in the treatment of chronic inflammatory diseases with initiation of the era of biologics. However, an unmet medical need still exists for novel targeted therapies. Compared with biologics, Janus kinase inhibitors (JAKis) are a new drug class of orally administered small molecules that have been shown to efficiently modulate complex cytokine-driven inflammation in preclinical models and human studies. Unfortunately, serious adverse effects have been reported with the first introduced pan-JAKi, tofacitinib. Here, we review tyrosine kinase 2 (TYK2) signaling in the pathophysiology of inflammatory bowel disease (IBD), examine mechanisms of action of selective TYK2 inhibitors (TYK2is), and discuss the potential for these inhibitors in efforts to balance benefits and harms.

AB - Recent significant advances have been made in the treatment of chronic inflammatory diseases with initiation of the era of biologics. However, an unmet medical need still exists for novel targeted therapies. Compared with biologics, Janus kinase inhibitors (JAKis) are a new drug class of orally administered small molecules that have been shown to efficiently modulate complex cytokine-driven inflammation in preclinical models and human studies. Unfortunately, serious adverse effects have been reported with the first introduced pan-JAKi, tofacitinib. Here, we review tyrosine kinase 2 (TYK2) signaling in the pathophysiology of inflammatory bowel disease (IBD), examine mechanisms of action of selective TYK2 inhibitors (TYK2is), and discuss the potential for these inhibitors in efforts to balance benefits and harms.

KW - Crohn disease

KW - Janus kinase

KW - signal transducers and activators of transcription

KW - small molecules

KW - therapy

KW - tyrosine kinase 2

KW - ulcerative colitis

U2 - 10.1016/j.tips.2022.02.008

DO - 10.1016/j.tips.2022.02.008

M3 - Review

C2 - 35277286

AN - SCOPUS:85125935371

VL - 43

SP - 424

EP - 436

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

SN - 0165-6147

IS - 5

ER -

ID: 300671108